RxDoctor Payments Data

Steven Weinsier, MD

Cardiovascular Disease · Northampton, MANPI 1336366897

Payments from drug & device makers

$9,772in general payments, 2019–2025

Across 438 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Novartis$906
  • E.r. Squibb & Sons, L.L.C.$835
  • Amgen$800
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,766100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,772 in reported general payments places this provider in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$513,669
Medicare patients
3,477
Services billed
7,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban497$663,759
XareltoRivaroxaban182$253,650
EntrestoSacubitril/Valsartan117$143,785
Repatha SureclickEvolocumab102$98,675
JardianceEmpagliflozin49$53,488
MultaqDronedarone Hcl33$47,366
Praluent PenAlirocumab30$27,182
FarxigaDapagliflozin Propanediol34$23,298
Rosuvastatin Calcium528$22,445
BrilintaTicagrelor32$19,964
Metoprolol Succinate686$15,094
Atorvastatin Calcium613$12,577
Diltiazem 24hr Er (Cd)Diltiazem Hcl210$10,634
Ezetimibe149$8,876
Flecainide Acetate137$8,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,032$663,759497 claims
Johnson & JohnsonXarelto$1,298$253,650182 claims
NovartisEntresto$906$143,785117 claims
Boehringer IngelheimJardiance$290$53,48849 claims
Sanofi-aventis U.S. LLCMultaq$155$47,36633 claims
AstraZenecaFarxiga, Brilinta$1,012$43,26266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Northampton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →